The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions.

ABSTRACT: Antibodies targeting PD-1 have been demonstrated durable anti-cancer activity in certain cancer types. However, the anti-PD-1 antibodies are less or not efficacious in many situations, which might be attributed to co-expression of multiple inhibitory receptors or presence of immunosuppressive cells in the tumor microenvironment. Most of the anti-PD-1 antibodies used in clinical studies are of IgG4 isotype with the S228P mutation (IgG4_S228P). The functional impact by the interaction of anti-PD-1 IgG4_S228P antibody with Fc gamma receptors (FcγRs) is poorly understood. To assess the effects, we generated a pair of anti-PD-1 antibodies: BGB-A317/IgG4_S228P and BGB-A317/IgG4-variant (abbreviated as BGB-A317), with the same variable regions but two different IgG4

SUBMITTER: Zhang T 

PROVIDER: S-EPMC6006217 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature